Real World Outcomes Using Novel Agents for AML in the UK

Sponsor
Guy's and St Thomas' NHS Foundation Trust
Study ID
NCT05312112
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    Observational study of venetoclax in AML
  • Gilteritinib — DRUG
    Observational study of gilteritinib in AML

Study Details

This project will collect data on patients with acute myeloid leukemia in the United Kingdom who were treated with two new targeted therapies during the coronavirus pandemic

Key Dates

Start date
May 1, 2022
Status verified
Feb 2023
Primary completion
Oct 1, 2023
Completion
Oct 1, 2023

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: Venetoclax
    Venetoclax in newly diagnosed AML
  • Arm: FLT3 inhibitors
    FLT3 inhibitors including gilteritinib in relapsed AML

Primary Outcome Measure

Overall survival [ Time Frame: 1 year ]

Central Contacts

Related Studies